In last trading session, Mersana Therapeutics Inc (NASDAQ:MRSN) saw 2.81 million shares changing hands with its beta currently measuring 1.50. Company’s recent per share price level of $0.45 trading at -$0.06 or -12.19% at ring of the bell on the day assigns it a market valuation of $55.85M. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.17 million shares which gives us an average trading volume of 5.59 million if we extend that period to 3-months.

For Mersana Therapeutics Inc (MRSN), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.40. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.19 in the current quarter.

Mersana Therapeutics Inc (NASDAQ:MRSN) trade information

Upright in the red during last session for losing -12.19%, in the last five days MRSN remained trading in the red while hitting it’s week-highest on Friday, 03/07/25 when the stock touched $0.45 price level, adding 18.88% to its value on the day. Mersana Therapeutics Inc’s shares saw a change of -68.66% in year-to-date performance and have moved -14.68% in past 5-day. Mersana Therapeutics Inc (NASDAQ:MRSN) showed a performance of -32.65% in past 30-days. Number of shares sold short was 10.32 million shares which calculate 2.26 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 3 to the stock, which implies a rise of 85.0% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 3. It follows that stock’s current price would drop -566.67% in reaching the projected high whereas dropping to the targeted low would mean a loss of -566.67% for stock’s current value.

Mersana Therapeutics Inc (MRSN) estimates and forecasts

This year revenue growth is estimated to fall -33.05% from the last financial year’s standing.

9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 6.04M for the same. And 9 analysts are in estimates of company making revenue of 6.11M in the next quarter. Company posted 9.24M and 2.29M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 2.74% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -28.16% while estimates for its earnings growth in next 5 years are of -13.09%.

Mersana Therapeutics Inc (NASDAQ:MRSN)’s Major holders

Insiders are in possession of 1.40% of company’s total shares while institution are holding 85.51 percent of that, with stock having share float percentage of 86.72%. Investors also watch the number of corporate investors in a company very closely, which is 85.51% institutions for Mersana Therapeutics Inc that are currently holding shares of the company. ECOR1 CAPITAL, LLC is the top institutional holder at MRSN for having 19.36 million shares of worth $38.92 million. And as of 2024-06-30, it was holding 15.8156 of the company’s outstanding shares.

The second largest institutional holder is VR ADVISER, LLC, which was holding about 11.33 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.2519 of outstanding shares, having a total worth of $22.77 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 3.47 shares of worth $1.56 million or 2.78% of the total outstanding shares. The later fund manager was in possession of 3.11 shares on Dec 31, 2024 , making its stake of worth around $1.39 million in the company or a holder of 2.50% of company’s stock.